BriaCell Therapeutics Corp. Quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest in USD from Q2 2022 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
Summary
BriaCell Therapeutics Corp. quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest history and growth rate from Q2 2022 to Q2 2024.
  • BriaCell Therapeutics Corp. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest for the quarter ending July 31, 2024 was -$2.68M, a 28.9% increase year-over-year.
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Quarterly (USD)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 -$2.68M +$1.09M +28.9% Jul 31, 2024 10-K 2024-10-29
Q1 2024 -$6.23M -$341K -5.78% Apr 30, 2024 10-Q 2024-06-14
Q4 2023 -$8.32M -$7.04M -550% Jan 31, 2024 10-Q 2024-06-14
Q3 2023 $2.52M -$7.82M -75.7% Oct 31, 2023 10-Q 2024-03-18
Q2 2023 -$3.78M -$14.1M -137% Jul 31, 2023 10-K 2024-10-29
Q1 2023 -$5.89M Apr 30, 2023 10-Q 2024-06-14
Q4 2022 -$1.28M Jan 31, 2023 10-Q 2024-06-14
Q3 2022 $10.3M Oct 31, 2022 10-Q 2024-03-18
Q2 2022 $10.3M Jul 31, 2022 10-K 2024-10-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.